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Abstract Background: Since a study in orthopedic hip
fracture patients demonstrated that a liberal hemoglobin
(Hb) threshold does not improve patient morbidity and mor-
tality relative to a restrictive Hb threshold, the standard of
care in total joint arthroplasty (TJA) should be examined to
understand the variability of red blood cell (RBC) transfu-
sion following TJA. Questions/purposes: The study aimed
to answer the following questions: (1) What is the blood
utilization rate after primary TJA for individual surgeons
within a large hospital network? (2) What is the comparison
of hospital charges, length of stay (LOS), and discharge
locations among TJA patients who were and were not trans-
fused? Methods: A retrospective study was conducted on
3,750 primary total knee arthroplasties (TKAs) and 2,070
primary total hip arthroplasties (THAs), and data was retro-
spectively collected over a 15-month period on the number
of RBCs transfused per patient, along with demographic and
cost details. The number of patients who received at least 1
RBC unit and the number of RBCs transfused per patient
was calculated and stratified by surgeon. Results: In the
postoperative period, 19.3% TKA patients and 38.5% THA
patients received a RBC transfusion. Transfusion rates fol-
lowing TJA varied widely between surgeons (TKA 4.8–
63.8%, THA 4.3–86.8%). Transfused TKA patients received
an average of 1.65±0.03 RBCs, and THA patients received
an average of 1.97±0.14 RBCs. LOS and hospital charges
for blood transfusion patients were higher than nontrans-
fused patients. Conclusion: Blood utilization after primary
TJA varies greatly among surgeons, suggesting that resour-
ces may be misallocated. These findings highlight the need
to standardize RBC transfusion practice following TJA.
Keywords total joint arthroplasty.blood utilization.
transfusion rate.bloodmanagement.red blood cell
(RBC) transfusion.intervention
Introduction
The threshold for red blood cell (RBC) transfusion in the
postoperative surgical period has evolved over the years. In
1942, it was believed that it was ideal to maintain a hemoglo-
bin (Hb) and hematocrit (Hct) over 10.0 g/dL and 30.0 g/dL,
respectively, in high-risk surgical patients [1]. The need for
liberal blood transfusion (Hb>10.0 g/dL) was questioned
when a randomized, controlled trial comparing a liberal to a
restrictive RBC transfusion policy (transfuse if Hb<7.0 g/dL)
in hemodynamically stable intensive care unit (ICU) patients
demonstrated that there was no difference in 30-day mortality
or in cardiac events regardless of the Hb threshold employed
(Transfusion Requirements in Critical Care study, TRICC)
[10]. Thus began a trend towards lower RBC transfusion
thresholds in critically ill and general medicine patients.
A large, multicenter, randomized study evaluating trans-
fusion triggers in postoperative hip fracture patients with
cardiovascular disease or risk factors was recently published
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(@Functional Outcomes in Cardiovascular Patients Under-
going Surgical Hip Fracture Repair, FOCUS). The results
were similar to the TRICC trial in that there was no differ-
ence in mortality or functional outcomes between the
patients who were transfused following a restrictive strategy
(Hb<8.0 g/dL with symptoms of anemia) or the liberal
strategy (transfused to keep Hb>10.0 g/dL) [7, 8]. There is
growing interest to reduce the number of blood transfusions,
as blood administration is not benign and evidence-based
findings demonstrate that patients who undergo restrictive
transfusion guidelines are not clinically compromised [5, 6,
8]. The surgical literature has demonstrated a relationship
between blood transfusions and increased risks of surgical
site infection, morbidity, and even mortality, although a
causal mechanism between receipt of blood products and
these outcomes has not been established [2, 12, 13, 15, 22].
Additionally, there are associated costs with administering
and storing blood [19].
Given the FOCUS study data, we have an evidence-
based benchmark against which we can evaluate transfusion
practice in hip fracture patients with cardiovascular disease
or disease risk factors. However, there are currently no
standards within orthopedic surgery for transfusing a post-
operative total joint arthroplasty (TJA) patient, and it would
be prudent to conduct an analysis to establish a benchmark
for best practice for transfusing RBCs in TJA patients with
the goal of reducing practice variability. However, in order
to begin effecting a change in practice using benchmark data
in total knee arthroplasty (TKA) and total hip arthroplasty
(THA), it is necessary to understand the current RBC trans-
fusion practice among surgeons who perform TJAs.
Thus, the goals of this study were to answer the follow-
ing questions: (1) what is the blood utilization rate after
primary TJA for individual surgeons within a large hospital
network? (2) What is the comparison of hospital charges,
length of stay (LOS), and discharge locations among TJA
patients who were and were not transfused?
Methods and Materials
Following approval by the Quality Improvement Review
Committee at our institution, the electronic medical record
database was retrospectively queried to identify all surgeons
who performed 10 or more primary TKA (ICD-9 code
81.54) or 10 or more primary THA (ICD-9 code 81.51)
surgeries per year between June 1, 2009 and August 31,
2010. Surgeons were excluded if they performed less than
10 primary TKAs or THAs a year. Thus, there were a total of
50 surgeons who performed at least 10 TKAs during the
study period, and 33 surgeons who performed at least 10
THAs. The number of cases was determined by the number
of discharged primary TJA patients. During the study peri-
od, there were a total of 3,750 TKAs and 2,070 THAs, with
osteoarthritis being the most common diagnosis, followed
by avascular necrosis, congenital dysplasia, and rheumatoid
arthritis.
All patients were admitted to the hospital on the day of
surgery and underwent primary TJA. For the TKAs, most
patients underwent a medial parapatellar approach, although
the lateral parapatellar approach was occasionally used for
valgus knees. THAs were performed with a variety of
approaches, including posterior, modified Hardinge, direct
lateral, and anterior, depending on the comfort of the attend-
ing surgeon. Postoperatively, each patient underwent the
standard protocol of each attending surgeon, which included
pain control (with or without nerve blocks) and physical
therapy. The decision to transfuse patients often resulted
from a discussion between anesthesiologists, internal medi-
cine physicians, and orthopedic surgeons. Anesthesiologists
played a role in determining blood transfusion within the
operating room and the postoperative anesthesia care unit,
while internal medicine physicians and orthopedic surgeons
play a greater role preoperatively and postoperatively. Typ-
ically, the orthopedic surgeon was involved in the final
decision to transfuse. For this study, patients were followed
until the date of discharge from the hospital, so there was no
follow-up routine to monitor.
The following outcomes were examined in this study.
The blood utilization rate was determined for each surgeon
who met the inclusion criteria and reflected the proportion of
their patients who received at least one allogenic RBC unit
in the postoperative period. Other transfusion parameters
that were also calculated included the average number of
postoperative allogenic RBC units transfused to each patient
and the proportion of patients that received autologous
blood. The rates of transfusion of other blood products were
not evaluated due to the low number of platelets and plasma
that these patients received. Hospital LOS was calculated by
subtracting the patient's day of discharge from his/her day of
admission. Hospital charges, in US dollars, were based on
the hospital bill sent to patients and were not corrected for
inflation. Finally, discharge locations were recorded, differ-
entiating between discharges to either home or to a recovery
facility (e.g., skilled nursing facilities and rehabilitation
facilities).
For the statistical analysis of this study, the normality of
the data was assessed by the Kolmogorov–Smirnov test, and
continuous variables demonstrated non-normal curves; thus,
nonparametric testing was implemented. Regression analy-
sis was conducted comparing the number of TJAs performed
for each surgeon to the surgeon's transfusion rate and the
number of RBC units administered to each transfused pa-
tient. A statistical analysis for continuous variables (hospital
charges and LOS) was analyzed using Mann–Whitney U
tests. Discharge location analysis was performed by chi-
squared tests. Statistical significance was defined as a p
value <0.05. All statistical analyses were performed using
Predictive Analytics Software (PASW) version 18.0 (SPSS,
Chicago, IL, USA).
Results
Of the primary TKA patients, 19.3% (723/3,750) received a
transfusion and these patients received an average of 1.65±
0.03 U of RBCs in the postoperative period (Fig. 1a), while
THA patients had a greater number of transfusions (38.5%,
124 HSSJ (2013) 9:123–128
796/2,070) and the transfused patients received an average
of 1.97±0.14 U postoperatively (Fig. 1b). Within our health
care system, allogenic RBC transfusion rates following prima-
ry TKA varied greatly between individual surgeons (Fig. 2).
The lowest transfusion rate was 4.8% for a surgeon who
performed 104 primary TKAs per year (Fig. 2a); this surgeon
transfused an average of 1.2 U per transfusion event (i.e., a
transfused patient). On the other end of the spectrum, another
surgeon performed 69 TKAs during the study period, trans-
fused an average of 1.9 U per transfusion event, and had a
63.8% transfusion rate. For primary THAs, the transfusion
rates also varied widely between surgeons. The surgeon with
the lowest transfusion rate (4.3%) transfused an average of 1.5
U per transfusion event and performed 350 THAs during the
study period. The surgeon with the highest transfusion rate
(86.8%) transfused an average of 2.2 U per transfusion event
and performed 386 THAs (Fig. 2b). There was no correlation
between the number of cases performed and the transfusion
rate (TKA: R200.006, p00.613, THA: R200.019, p00.449)
or the average number of units transfused (TKA: R200.038,
p00.188, THA: R200.002, p00.790).
Hospital LOS significantly differed between those patients
that did and did not receive allogenic RBC transfusions. The
average LOS was significantly longer for TKA patients who
did receive a transfusion (4.0 days±2.1, median±standard
deviation) vs. those who did not receive a transfusion
(3.0 days±1.3, p<0.001). The average LOS for primary
THA patients who received an RBC transfusion was slightly
but significantly longer (3.5±0.2 days) compared to those who
did not receive a transfusion (3.2±0.2 days, p00.013).
Hospital charges were also significantly higher for
patients who received allogenic RBC transfusions compared
to those that did not receive a transfusion. The average
hospital charge for patients who received blood transfusions
after TKA ($61,548.25±$33,517.45) was significantly
higher than those that did not receive blood transfusions
($51,768.58±$25,921.78, p<0.001). The average hospital
charge for THA patients who received RBC transfusions
were also significantly higher ($82,588.60±$4,968.29) than
the charges for patients who did not receive transfusions
($64,845.60±$2,384.73, p00.002).
Finally, patients who received allogenic transfusions
were more likely to be discharged to a recovery facility as
opposed to home (Fig. 3). TKA patients who were trans-
fused were more likely to be discharged to a facility (37.7%)
than TKA patients who were not transfused (24.6%, p<
0.001, Fig. 3a). The results were similar for primary THA
patients (Fig. 3b). Of the transfused THA patients, 31.7%
were sent to a recovery facility and 68.3% were sent home.
Of the primary THA patients that were not transfused,
21.8% were sent to a facility, while 78.2% were sent home.
Patients who received transfusions were more likely to be
discharged to a facility as opposed to home (p<0.001).
Discussion
Establishing a postorthopedic surgery RBC transfusion
threshold in TJA patients has been a challenge due to the
lack of evidence. The data from the FOCUS trial demon-
strated that a restrictive RBC transfusion strategy did not
lead to worse mortality and morbidity outcomes compared
to a liberal transfusion strategy in hip fracture patients. To
establish an evidence-based benchmark for postoperative
blood transfusion in TJA patients, current practices must
be examined. Previous studies in Europe have demonstrated
that the perioperative RBC transfusion practices of surgeons
who perform TJAs at various hospitals varied greatly in
terms of the frequency with which patients were transfused
and the number of RBCs that individual patients received
[18, 21]. In order to change RBC transfusion practice fol-
lowing TJAs, the extent of the variability of current transfu-
sion practice among TJA surgeons needed to be established.
Thus, we examined blood utilization rates for individual
surgeons who performed primary TJA and compared hospi-
tal charges, LOS, and discharge locations for patients that
were and were not transfused in our health care system.
There are several limitations with this study. This was a
retrospective study, and we could not collect specific demo-
graphic data on the patients in this study. This study did not
include analysis of demographic variables, including age,
ASA, preoperative functioning level, preoperative Hb, and
length of time in hospital awaiting rehabilitation placement.
Fig. 1. Flow chart describing the transfusion populations. a Total knee
arthroplasty (TKA), b total hip arthroplasty (THA).
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Thus, we cannot exclude the possibility that the patients who
received allogenic RBC transfusions might have been sicker or
more anemic than those who did not require a transfusion; this
possibility would confound the correlation between receipt of a
transfusion and LOS, total hospital costs, and potentially, the
location to which patients were discharged. A multivariate
analysis is needed to analyze these individual variables to
determine if blood transfusions are an independent risk factor
for increased LOS, increased hospital costs, and discharge to a
rehabilitation facility. The lack of individual patient demo-
graphic information also prevented an analysis of why the
patients were transfused and at what Hb concentration they
were transfused. Furthermore, other factors, such as postoper-
ative mortality, postoperative morbidity, and return to hospital,
were not evaluated in this study. This study could not evaluate
whether surgeons who had lower transfusion rates had higher
morbidity or mortality, or if patients of these surgeons were
more likely to return to the hospital for transfusions.
Fig. 2. Comparison of individual surgeons by the relation of the number of cases performed during the study period, the transfusion rate, and the
average number of units of red blood cells (RBCs) transfused per transfusion episode. The size of the circle is indicative of the number of cases
performed per surgeon. The surgeon with the highest transfusion rate is indicated with a dashed arrow and the surgeon with the lowest transfusion
rate is indicated with a solid arrow. a Total knee arthroplasty (TKA), b total hip arthroplasty (THA).
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Additionally, inconsistent RBC transfusion practices by indi-
vidual surgeons (i.e., transfusing patients at variable Hb thresh-
olds or for variable indications) would also confound this
analysis. Finally, we could not collect data to determine if any
blood conservation techniques were employed (e.g., regional
hypotensive anesthesia, hemodilution, pharmacologic, intrao-
perative blood salvage methods, and autotransfusion drains).
Utilizing these techniques could potentially confound postop-
erative transfusion rates, as patients may not have required
postoperative RBCs transfusions if intra- and postoperative
blood conserving techniques were used.
This study demonstrated that the transfusion rates were
highly variable between surgeons who perform primary TJA
in a similar geographic population of patients. There was a
large spread between the surgeon who transfused the greatest
number of patients and the surgeon who transfused the fewest;
for TKA, the difference in transfusion rate was 59.0% (range
4.8–63.8%), and for THA, the difference in transfusion rate
was 82.5% (range 4.3–86.8%). The variability seen in blood
utilization in this study may be related to differences in tech-
nique between individual surgeons and the evidence base upon
which postoperative transfusion decisions were made. For
THAs, the surgeons with the highest and lowest transfusion
rates both performed greater than 300 THAs yearly. The two
surgeons differed with the surgical approach performed, where
the surgeon with a higher transfusion rate performs minimally
invasive two-incision approach, and the surgeon with the lower
transfusion performs a minimally invasive posterior approach.
One surgeon's minimally invasive protocol transfused RBC in
patients to treat postoperative dizziness and to enable quicker
recovery. The other surgeon's minimally invasive protocol
limited RBC transfusions. In a multicenter study conducted
in Canada that evaluated surgeons' triggers for transfusion after
TJA, it was determined that Hb concentration was the predom-
inant determination of transfusion [21]. However, this study
and other studies conducted in Europe and Canada, looked at
the aggregate of surgeons and not individual surgeons [9, 11,
16, 18]. In order to implement evidence-based transfusion
thresholds, it is necessary to understand the practices and
beliefs that underlie each surgeon's decision to transfuse or
not to transfuse. Thus, this study uniquely looked at individual
surgeons and their transfusion rates in relation to the number of
TJAs they performed annually.
This study also demonstrated that primary TJA patients
who received transfusions had shorter LOS, lower hospital
charges, and were more likely to be discharged home. These
findings have also been shown in cardiac surgery, vascular
surgery, and ICU patients [3, 4, 10, 14, 17] but have never
been done in TJA patients. With the creation of accountable
care organizations or a type of payment model that ties pro-
vider reimbursements to certain quality measures and reduc-
tions in costs for specific patient populations, standardizing
medical practice will become necessary in order to achieve
potential cost savings. One way of reducing the costs associ-
ated with transfusions may be to encourage the preoperative
optimization of the patient's Hb concentration by the surgeons
themselves or through referral to a primary care doctor or to a
clinic designed to diagnose and treat preoperative anemia.
Since previous studies have shown that a restrictive RBC
transfusion threshold does not increase morbidity or mortality
in hip surgery patients, it is imperative that benchmarks also be
established in TJA patients and that practice guidelines are
made to reflect the current evidence base. To that end, the
current standard of practice for individual surgeons performing
primary TJA in a large hospital network was assessed for their
blood transfusion rates in the postoperative period; our study
demonstrated that there was great variation in transfusion prac-
tice among these surgeons, which might have been responsible
for the variability in the outcomes demonstrated in this study.
Our study also demonstrated that transfused patients tend
to stay in the hospital longer, thereby amassing greater costs
and were less likely to have been discharged home. Thus,
establishing evidence-based criteria to reduce blood trans-
fusions after TJA may minimize costs and decrease hospital
LOS in TJA patients. This study was designed to capture the
practice of orthopedic surgeons and their blood utilization
rates to better understand their views. Thus, the results of our
quality improvement study have been presented as a bench-
marking tool to vice presidents of operations at individual
hospitals within our system, surgeons who were studied, and
staff to educate them on the efficacy of a limited transfusion
protocol. By showing individual surgeons their transfusion
rates, surgeons have responded by changing their
Fig. 3. Discharge location. Primary a total knee arthroplasty (TKA)
and b total hip arthroplasty (THA) patients who were not transfused
were more likely to be discharged to home as opposed to a facility
(skilled nursing facility, rehabilitation facility, etc.).
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transfusion practices [20], with a few outliers. Future quality
improvements studies will examine if awareness of this
benchmarking study can enact standardized practice guide-
line changes in surgeon transfusion practices by reducing
allogenic RBC transfusions from outlier surgeons.
Appropriately allocating blood product resources for
transfusions after primary TKA may require the standardi-
zation of formal transfusion criteria. Future directions for
studies include prospectively examining transfusion triggers
for individual surgeons performing primary TJA and deter-
mining universal guidelines by which orthopedic surgeons
should transfuse primary TJA patients to ensure optimal
patient outcomes.
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